Neurocrine [NBIX] vs Zoetis [ZTS] Detailed Stock Comparison
Neurocrine
NASDAQ
Loading...
Zoetis
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Neurocrine wins in 9 metrics, Zoetis wins in 10 metrics, with 0 ties. Zoetis appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Neurocrine | Zoetis | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 39.32 | 25.36 | Zoetis |
| Price-to-Book Ratio | 4.88 | 13.14 | Neurocrine |
| Debt-to-Equity Ratio | 18.18 | 137.01 | Neurocrine |
| PEG Ratio | 0.56 | 23.24 | Neurocrine |
| EV/EBITDA | 24.06 | 17.91 | Zoetis |
| Profit Margin (TTM) | 13.88% | 27.83% | Zoetis |
| Operating Margin (TTM) | 21.18% | 40.20% | Zoetis |
| EBITDA Margin (TTM) | 21.18% | 40.20% | Zoetis |
| Return on Equity | 13.39% | 52.77% | Zoetis |
| Return on Assets (TTM) | 8.67% | 15.37% | Zoetis |
| Free Cash Flow (TTM) | $557.20M | $2.30B | Zoetis |
| Dividend Yield | N/A | 1.11% | N/A |
| 1-Year Return | -8.35% | -16.11% | Neurocrine |
| Price-to-Sales Ratio (TTM) | 5.25 | 6.96 | Neurocrine |
| Enterprise Value | $12.70B | $70.67B | Zoetis |
| EV/Revenue Ratio | 5.06 | 7.53 | Neurocrine |
| Gross Profit Margin (TTM) | 98.36% | 73.62% | Neurocrine |
| Revenue per Share (TTM) | $25 | $21 | Neurocrine |
| Earnings per Share (Diluted) | $3.38 | $5.81 | Zoetis |
| Beta (Stock Volatility) | 0.25 | 0.88 | Neurocrine |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Neurocrine vs Zoetis Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Neurocrine | 1.21% | 6.31% | 1.26% | 10.50% | 16.61% | -3.60% |
| Zoetis | 1.51% | 4.59% | 0.82% | -3.89% | -1.51% | -5.23% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Neurocrine | -8.35% | 24.21% | 17.50% | 203.77% | 2,152.54% | 182.11% |
| Zoetis | -16.11% | -9.09% | -2.69% | 242.31% | 396.97% | 396.97% |
Performance & Financial Health Analysis: Neurocrine vs Zoetis
| Metric | NBIX | ZTS |
|---|---|---|
| Market Information | ||
| Market Cap | $13.18B | $65.30B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 982,180 | 4,111,510 |
| 90 Day Avg. Volume | 974,667 | 3,459,870 |
| Last Close | $132.90 | $167.10 |
| 52 Week Range | $84.23 - $154.87 | $139.70 - $200.33 |
| % from 52W High | -14.19% | -16.59% |
| All-Time High | $157.98 (Jul 29, 2024) | $249.27 (Dec 27, 2021) |
| % from All-Time High | -15.88% | -32.96% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.17% | 0.04% |
| Quarterly Earnings Growth | 0.65% | 0.15% |
| Financial Health | ||
| Profit Margin (TTM) | 0.14% | 0.28% |
| Operating Margin (TTM) | 0.21% | 0.40% |
| Return on Equity (TTM) | 0.13% | 0.53% |
| Debt to Equity (MRQ) | 18.18 | 137.01 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $27.22 | $11.21 |
| Cash per Share (MRQ) | $9.84 | $3.28 |
| Operating Cash Flow (TTM) | $567.30M | $2.93B |
| Levered Free Cash Flow (TTM) | $367.04M | $2.29B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.11% |
| Last 12-Month Dividend | N/A | $1.86 |
Valuation & Enterprise Metrics Analysis: Neurocrine vs Zoetis
| Metric | NBIX | ZTS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 39.32 | 25.36 |
| Forward P/E | 21.40 | 23.24 |
| PEG Ratio | 0.56 | 23.24 |
| Price to Sales (TTM) | 5.25 | 6.96 |
| Price to Book (MRQ) | 4.88 | 13.14 |
| Market Capitalization | ||
| Market Capitalization | $13.18B | $65.30B |
| Enterprise Value | $12.70B | $70.67B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 5.06 | 7.53 |
| Enterprise to EBITDA | 24.06 | 17.91 |
| Risk & Other Metrics | ||
| Beta | 0.25 | 0.88 |
| Book Value per Share (MRQ) | $27.22 | $11.21 |
Financial Statements Comparison: Neurocrine vs Zoetis
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | NBIX | ZTS |
|---|---|---|
| Revenue/Sales | $572.60M | $2.22B |
| Cost of Goods Sold | $9.20M | $622.00M |
| Gross Profit | $563.40M | $1.60B |
| Research & Development | $263.20M | $157.00M |
| Operating Income (EBIT) | $23.70M | $846.00M |
| EBITDA | $40.30M | $991.00M |
| Pre-Tax Income | $14.70M | $810.00M |
| Income Tax | $6.80M | $179.00M |
| Net Income (Profit) | $7.90M | $631.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | NBIX | ZTS |
|---|---|---|
| Cash & Equivalents | $194.10M | $1.72B |
| Total Current Assets | $1.64B | $5.88B |
| Total Current Liabilities | $522.90M | $3.39B |
| Long-Term Debt | $447.50M | $5.40B |
| Total Shareholders Equity | $2.54B | $4.66B |
| Retained Earnings | $-5.30M | $12.38B |
| Property, Plant & Equipment | $589.20M | $6.36B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | NBIX | ZTS |
|---|---|---|
| Operating Cash Flow | $21.80M | $567.00M |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | $54.10M | $438.00M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | $-150.00M | $-443.00M |
Short Interest & Institutional Ownership Analysis
| Metric | NBIX | ZTS |
|---|---|---|
| Shares Short | 2.85M | 7.85M |
| Short Ratio | 3.10 | 2.67 |
| Short % of Float | 0.04% | 0.02% |
| Average Daily Volume (10 Day) | 982,180 | 4,111,510 |
| Average Daily Volume (90 Day) | 974,667 | 3,459,870 |
| Shares Outstanding | 99.40M | 448.47M |
| Float Shares | 98.00M | 442.37M |
| % Held by Insiders | 0.01% | 0.00% |
| % Held by Institutions | 1.01% | 0.98% |
Dividend Analysis & Yield Comparison: Neurocrine vs Zoetis
| Metric | NBIX | ZTS |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.86 |
| Last 12-Month Dividend Yield | N/A | 1.11% |
| 3-Year Avg Annual Dividend | N/A | $1.63 |
| 3-Year Avg Dividend Yield | N/A | 0.24% |
| 3-Year Total Dividends | N/A | $4.90 |
| Ex-Dividend Date | N/A | Apr 21, 2025 |